ReviewCellular and molecular life sciences : CMLS2021
Generation and manipulation of human iPSC-derived platelets.
Review in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Proteomics of heterogeneous megakaryocytes identifies JI051 as an enhancer of platelet biogenesis.Life science alliance · 2026Article
- Laboratory Assessment and Clinical Outlook forAnnals of laboratory medicine · 2026Review
- Article
- Redox Regulation of Megakaryocyte Differentiation and Platelet Biogenesis.Antioxidants (Basel, Switzerland) · 2026Review
- Scalable bioreactor manufacturing of iPSC-derived megakaryocytes with Proanthocyanidin A supplementation: a strategic platform for military blood supply resilience.Military Medical Research · 2026Article
- STAT1-mediated epigenetic regulation of LIN28A controls iPSC-derived platelet production through the let-7-RALB axis.Blood advances · 2025Article
- Cell-based artificial platelet production: historical milestones, emerging trends, and future directions.Blood research · 2025Review
- Megakaryocyte in sepsis: the trinity of coagulation, inflammation and immunity.Critical care (London, England) · 2024Review
- Induced Pluripotent Stem Cells in Birds: Opportunities and Challenges for Science and Agriculture.Veterinary sciences · 2024Review
- Applications, Limitations, and Considerations of Clinical Trials in a Dish.Bioengineering (Basel, Switzerland) · 2024Review
- Megakaryocyte-induced contraction of plasma clots: cellular mechanisms and structural mechanobiology.Blood · 2024Article
- Platelet-Rich Plasma in Dermatology: New Insights on the Cellular Mechanism of Skin Repair and Regeneration.Life (Basel, Switzerland) · 2023Review
- Baffled-flow culture system enables the mass production of megakaryocytes from human embryonic stem cells by enhancing mitochondrial function.Cell proliferation · 2023Article
- Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets.International journal of hematology · 2023Review
- Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.Blood advances · 2022Article
- Evaluation and management of platelet transfusion refractoriness.Blood research · 2022Review
- Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.Stem cell research & therapy · 2022Article
- Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.Frontiers in immunology · 2022Article
- Improving Human Induced Pluripotent Stem Cell-Derived Megakaryocyte Differentiation and Platelet Production.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The discovery of iPSCs has led to the ex vivo production of differentiated cells for regenerative medicine. In the case of transfusion products, the derivation of platelets from iPSCs is expected to complement our current blood-donor supplied transfusion system through donor-independent production with complete pathogen-free assurance. This derivation can also overcome alloimmune platelet transfusion refractoriness by resulting in autologous, HLA-homologous or HLA-deficient products. Several developments were necessary to produce a massive number of platelets required for a single transfusion. First, expandable megakaryocytes were established from iPSCs through transgene expression. Second, a turbulent-type bioreactor with improved platelet yield and quality was developed. Third, novel drugs that enabled efficient feeder cell-free conditions were developed. Fourth, the platelet-containing suspension was purified and resuspended in an appropriate buffer. Finally, the platelet product needed to be assured for competency and safety including non-tumorigenicity through in vitro and in vivo preclinical tests. Based on these advancements, a clinical trial has started. The generation of human iPSC-derived platelets could evolve transfusion medicine to the next stage and assure a ubiquitous, safe supply of platelet products. Further, considering the feasibility of gene manipulations in iPSCs, other platelet products may bring forth novel therapeutic measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.